Metabotropic Glutamate Receptor 7: From Synaptic Function to Therapeutic Implications
- PMID: 27306064
- PMCID: PMC4983754
- DOI: 10.2174/1570159x13666150716165323
Metabotropic Glutamate Receptor 7: From Synaptic Function to Therapeutic Implications
Abstract
Metabotropic glutamate receptor 7 (mGluR7) is localized presynaptically at the active zone of neurotransmitter release. Unlike mGluR4 and mGluR8, which share mGluR7's presynaptic location, mGluR7 shows low affinity for glutamate and is activated only by high glutamate concentrations. Its wide distribution in the central nervous system (CNS) and evolutionary conservation across species suggest that mGluR7 plays a primary role in controlling excitatory synapse function. High mGluR7 expression has been observed in several brain regions that are critical for CNS functioning and are involved in neurological and psychiatric disorder development. Until the recent discovery of selective ligands for mGluR7, techniques to elucidate its role in neural function were limited to the use of knockout mice and gene silencing. Studies using these two techniques have revealed that mGluR7 modulates emotionality, stress and fear responses. N,N`-dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082) was reported as the first selective mGluR7 allosteric agonist. Pharmacological effects of AMN082 have not completely confirmed the mGluR7-knockout mouse phenotype; this has been attributed to rapid receptor internalization after drug treatment and to the drug's apparent lack of in vivo selectivity. Therefore, the more recently developed mGluR7 negative allosteric modulators (NAMs) are crucial for understanding mGluR7 function and for exploiting its potential as a target for therapeutic interventions. This review presents the main findings regarding mGluR7's effect on modulation of synaptic function and its role in normal CNS function and in models of neurologic and psychiatric disorders.
Conflict of interest statement
All the authors have read and approved the paper and have not any financial or other relationships that might lead to a conflict of interest.
Figures

Similar articles
-
A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo.Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18712-7. doi: 10.1073/pnas.0508063102. Epub 2005 Dec 9. Proc Natl Acad Sci U S A. 2005. PMID: 16339898 Free PMC article.
-
Metabotropic glutamate receptor 7: at the interface of cognition and emotion.Eur J Pharmacol. 2010 Aug 10;639(1-3):123-31. doi: 10.1016/j.ejphar.2010.02.059. Epub 2010 Apr 2. Eur J Pharmacol. 2010. PMID: 20371242 Review.
-
mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082.Neuropharmacology. 2007 Jan;52(1):108-17. doi: 10.1016/j.neuropharm.2006.07.020. Epub 2006 Aug 17. Neuropharmacology. 2007. PMID: 16914173
-
Off-target potential of AMN082 on sleep EEG and related physiological variables: Evidence from mGluR7 (-/-) mice.Behav Brain Res. 2016 Sep 15;311:287-297. doi: 10.1016/j.bbr.2016.05.035. Epub 2016 May 17. Behav Brain Res. 2016. PMID: 27211063
-
Nociception modulation by supraspinal group III metabotropic glutamate receptors.J Neurochem. 2017 May;141(4):507-519. doi: 10.1111/jnc.13725. Epub 2017 Feb 22. J Neurochem. 2017. PMID: 27363363 Review.
Cited by
-
Synaptic adhesion protein ELFN1 is a selective allosteric modulator of group III metabotropic glutamate receptors in trans.Proc Natl Acad Sci U S A. 2018 May 8;115(19):5022-5027. doi: 10.1073/pnas.1722498115. Epub 2018 Apr 23. Proc Natl Acad Sci U S A. 2018. PMID: 29686062 Free PMC article.
-
Discovery of CVN636: A Highly Potent, Selective, and CNS Penetrant mGluR7 Allosteric Agonist.ACS Med Chem Lett. 2023 Mar 2;14(4):442-449. doi: 10.1021/acsmedchemlett.2c00529. eCollection 2023 Apr 13. ACS Med Chem Lett. 2023. PMID: 37077399 Free PMC article.
-
Pathogenic GRM7 Mutations Associated with Neurodevelopmental Disorders Impair Axon Outgrowth and Presynaptic Terminal Development.J Neurosci. 2021 Mar 17;41(11):2344-2359. doi: 10.1523/JNEUROSCI.2108-20.2021. Epub 2021 Jan 26. J Neurosci. 2021. PMID: 33500274 Free PMC article.
-
mGluR7 allosteric modulator AMN082 corrects protein synthesis and pathological phenotypes in FXS.EMBO Mol Med. 2024 Mar;16(3):506-522. doi: 10.1038/s44321-024-00038-w. Epub 2024 Feb 19. EMBO Mol Med. 2024. PMID: 38374465 Free PMC article.
-
The Cold Case of Metabotropic Glutamate Receptor 6: Unjust Detention in the Retina?Curr Neuropharmacol. 2020;18(2):120-125. doi: 10.2174/1570159X17666191001141849. Curr Neuropharmacol. 2020. PMID: 31573889 Free PMC article. Review.
References
-
- Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997;37:205–237. [http://dx.doi.org/10.1146/annurev.pharmtox.37.1.205]. [PMID: 9131252]. - PubMed
-
- Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. 2005;4(2):131–144. [http://dx.doi.org/10.1038/nrd1630]. [PMID: 15665858]. - PubMed
-
- Ferraguti F., Shigemoto R. Metabotropic glutamate receptors. Cell Tissue Res. 2006;326(2):483–504. [http://dx.doi.org/10.1007/ s00441-006-0266-5]. [PMID: 16847639]. - PubMed
-
- Ritter S.L., Hall R.A. Fine-tuning of GPCR activity by receptor-interacting proteins. Nat. Rev. Mol. Cell Biol. 2009;10(12):819–830. [http://dx.doi.org/10.1038/nrm2803]. [PMID: 19935667]. - PMC - PubMed
-
- Shigemoto R., Kulik A., Roberts J.D., Ohishi H., Nusser Z., Kaneko T., Somogyi P. Target-cell-specific concentration of a metabotropic glutamate receptor in the presynaptic active zone. Nature. 1996;381(6582):523–525. [http://dx.doi.org/10.1038/ 381523a0]. [PMID: 8632825]. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources